Results 191 to 200 of about 33,041 (261)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications. [PDF]

Virol J
Meshref M, Hussein AS, Allam SA, Moghib K, Younis H, Shalaby N.   +5 more
europepmc   +1 more source

Current Status of Kidney Xenotransplantation in Basic Research

Organ Medicine, Volume 3, Issue 2, Page 87-101, June 2026.
Kidney xenotransplantation is a potential solution to the organ shortage for end‐stage kidney disease. This review systematically elaborates on the application advances of donor pig gene editing technologies, the molecular mechanisms and regulatory strategies of xenogeneic immune rejection, and the optimization approaches of immune compatibility ...
Yu Luo, Bingzhuo Liu, Weijie Lai
wiley   +1 more source

Bivalent aptamer assemblies: A versatile toolkit for precision targeting of B-cell malignancies. [PDF]

Mol Ther Nucleic Acids
Yin L.
europepmc   +1 more source

Real‐world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B‐cell lymphoma: A study from the GELTAMO network

HemaSphere, Volume 10, Issue 6, June 2026.
Mariana Bastos‐Oreiro, Gloria Iacoboni, Victor Navarro, Carolina Martínez, Pablo Manresa, Laura Magnano, Ana Jiménez‐Ubieto, Sofia Vázquez, María José Rodriguez, Maria Teresa Busnego, Raquel Del Campo, Pedro José Paúl, Ilda Murillo, Eva María Donato, Angel Serna, Hugo Luzardo, Pilar Gómez, Elena Pérez, Begoña Mendibil, Sergio Ramos, Ana García‐Noblejas, Sonia Gonzalez de Villambrosia, Francisco Javier Díaz, Javier López, Fernando Martín‐Moro, Paula Fernandez‐Caldas, Ruben Fernandez, Antonio Gutierrez, Blanca Sánchez, Nazaret Domínguez, María Civeira, Paola Villafuerte, Iñigo Olazabal, Izaskun Zeberio, Cristina Barrenetxea, Norma Gutierrez, Samuel Romero, Sofía Martín‐Consuegra, Sofia Huerga, Nuria Golbano, Rosaía Riaza, Jose Antonio Hueso, Pilar Martinez‐Barranco, Belen Navarro, Lucía Villalón, Paula Ortega, Ana Torres, Iñigo Ormenazabal, María Piva Sanchez Anton, María Angeles Goñi, Pau Abrisqueta, Alejandro Martín García‐Sancho   +51 more
wiley   +1 more source

Association of Body Mass Index with SARS‐CoV‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings

International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.
ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran, Siaw Ing Yeo, Yi Xin Ng, Rosa Lim, Stephanie Wong, Stanley Angkodjojo, Andrew Yu Keat Khor, Li Wearn Koh, Manjari Lahiri, Margaret Ma   +9 more
wiley   +1 more source

Research Advances in Rituximab-Resistant Membranous Nephropathy. [PDF]

Kidney Med
Li K, Liu W, Wu D, Su Z, Wan Q.
europepmc   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

British Journal of Haematology, Volume 208, Issue 6, Page 2026-2035, June 2026.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes   +15 more
wiley   +1 more source

Aberrant B cell responses as drivers of autoantibody generation and epitope diversification in SLE pathogenesis. [PDF]

Front Immunol
Tariq F, Charavanmuttu Y, Labiba K, Wincup C.   +3 more
europepmc   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source